GE HealthCare Technologies Inc. (GEHC) Form 10-Q — Oct 28, 2026
GE HealthCare reported Q3 2026 revenue of $5,513 million, up 7.2% as reported and 6.2% organically, with diluted EPS of $1.36 versus $0.98 a year ago. Growth was broad-based across segments, led by PDx (up 13.0%) and AIS (up 6.1%, helped by the Intelerad acquisition). Tariffs remain a headwind but are easing: direct tariffs cut operating income by $53 million in Q3 ($209 million for nine months), while IEEPA tariff refunds delivered $9 million of pre-tax benefit in Q3 and $115 million for nine months, and the company says it will keep filing refund claims.
Key figures
- Eps
- 1.36
- Revenue
- 5513000000
- Net Income
- 615000000
- Total Debt
- 9973000000
- Revenue Yoy
- 7.2%
- Total Assets
- 38371000000
- Cash Position
- 2854000000
- Shares Outstanding
- 452137831
- Rpo total
- $16,113 million
- Adjusted eps q3
- $1.34
- Q3 2025 revenue
- $5,143 million
- Adjusted ebit q3
- $913 million
- Nine month revenue
- $15,939 million
- Operating income q3
- $805 million
- Q3 2025 eps diluted
- $0.98
- Buyback availability
- $500 million
- Effective tax rate q3
- 17.1% vs 27.8% prior year
- Nine month eps diluted
- $3.44
- Organic revenue growth q3
- 6.2%
- Free cash flow nine months
- $973 million
- Intelerad acquisition price
- $2,293 million net of cash
- Direct tariff impact q3 operating income
- -$53 million
- Tariff refund pretax benefit nine months
- $115 million
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.